Cynthia Silvia Bartolomeo

Cynthia Silvia Bartolomeo

Auto-generated profile, based on publicly available information

Cynthia Silvia Bartolomeo

Department of Physiological Sciences, Santa Casa de São Paulo School of Medical Sciences (FCMSCSP), São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
TBTaysa Bervian Bassani
Taysa Bervian Bassani
CBCynthia Silva Bartolomeo
Cynthia Silva Bartolomeo
RORafaela Brito Oliveira
Rafaela Brito Oliveira
RURodrigo Ureshino
Rodrigo Ureshino
Neuroactive steroids can be synthetic or endogenous molecules produced by neuronal and glial cells and peripheral glands. Examples include estrogens, testosterone, progesterone and its reduced metabolites such as 5α-dihydro­progesterone and allopregnanolone. Steroids produced by neurons and glia target the nervous system and are called neurosteroids. Progesterone and analog molecules, known as progestogens, have been shown to exhibit neurotrophic, neuroprotective, antioxidant, anti-inflammatory, glial modulatory, promyelinating, and remyelinating effects in several experimental models of neurodegenerative and injury conditions. Pleiotropic mechanisms of progestogens may act synergistically to prevent neuron degeneration, astrocyte and microglial reactivity, reducing morbidity and mortality. The aim of this review is to summarize the significant findings related to the actions of progesterone and other progestogens in experimental models and epidemiological and clinical trials of some of the most prevalent and debilitating chronic neurodegenerative disorders, namely, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. We evaluated progestogen alterations under pathological conditions, how pathology modifies their levels, as well as the intracellular mechanisms and glial interactions underlying their neuroprotective effects. Furthermore, an analysis of the potential of natural progestogens and synthetic progestins as neuroprotective and regenerative agents, when administered as hormone replacement therapy in menopause, is also discussed.

23 October 2026 in Current Gene Therapy
Verified
Journal Article
Closed access
PDF file
STSara Carolina Vieira Terra
Sara Carolina Vieira Terra
CBCynthia Silvia Bartolomeo
Cynthia Silvia Bartolomeo
SSSofia Mila Cantu de Sales
Sofia Mila Cantu de Sales
DIDaniel de Santa Inez
Daniel de Santa Inez
DTDavi Coe Torres
Davi Coe Torres
RSRoberta Stilhano
Roberta Stilhano
Introduction: Peripheral artery disease (PAD) reduces tissue perfusion and causes ischemia, conditions in which hypoxia-responsive pathways have an important adaptive role. Hypoxia- inducible factor 1-alpha (HIF-1α), a central regulator of this response, is tightly controlled by prolyl hydroxylase domain protein 2 (PHD2), encoded by EGLN1. Here, we used an RNA-targeting CRISPR-Cas13d system to downregulate EGLN1 in human umbilical vein endothelial cells (HUVECs) under normoxia and hypoxia. Methods: A PHD2-knockdown (PHD2-KD) HUVEC line was generated by lentiviral delivery of an EGLN1-targeting RNA guide, alongside non-transduced (CTRL) and non-targeting gRNA (NTG) control lines. Molecular and functional assays assessed hypoxia-related signaling, metabolic activity, migration, and sprouting responses under normoxia and hypoxia. results: PHD2-KD HUVECs showed significantly increased VEGFA expression under both normoxia and hypoxia, at the mRNA level (7.0-fold and 5.4-fold, respectively) and protein level (6.6-fold and 9.4-fold, respectively). At early time points (3–12 h), HIF-1α gene and protein levels were elevated, accompanied by reduced inflammatory cytokine levels, with TNF-α becoming undetectable after 48 h. Functionally, PHD2-KD cells showed enhanced proliferation, faster wound closure (2.0-fold under normoxia and 2.2-fold under hypoxia), and increased sprouting activity, with up to 5.4-fold more sprouts per bead and sprouts up to 2.5-fold longer than controls. Results: Western blotting confirmed a marked reduction in PHD2 protein abundance in PHD2-KD cells relative to both CTRL and NTG cells. PHD2-KD HUVECs exhibited increased VEGFA transcript levels (6.5-fold under normoxia and 5.3-fold under hypoxia) and secreted VEGF concentrations (6.6-fold and 9.4-fold, respectively), together with early increases in HIF1A transcript and HIF-1α protein levels and lower TNF-α concentrations. Functional assays showed higher metabolic activity, faster wound closure (2.0-fold under normoxia and 2.2-fold under hypoxia), and enhanced sprouting, with up to 7.2-fold more sprouts per bead and sprouts up to 2.7-fold longer than those formed by CTRL. Discussion: CRISPR-Cas13d-mediated EGLN1 targeting reduced PHD2 protein abundance and was associated with higher endothelial metabolic activity, faster wound closure, enhanced sprouting behavior, and lower TNF-α secretion. Conclusion: CRISPR-Cas13d-mediated downregulation of EGLN1/PHD2 was associated with increased pro-angiogenic signaling and improved angiogenesis-related endothelial responses in vitro, supporting RNA-targeting strategies to modulate hypoxia-responsive pathways.